Efficacy and safety of stem cell therapy for dry eye syndrome in Sjögren's syndrome: a systematic review and meta-analysis
Zhang J., Wang W., Li C.
Meta-analysis with a reported sample of 114, published in Front Immunol (2026) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Meta-analysis
- Journal
- Front Immunol (2026)
- Reported sample size
- 114
- Source database
- Europe PMC
- PMID
- 42158867
- PMCID
- PMC13182517
- DOI
- 10.3389/fimmu.2026.1834453
Abstract (original English)
Background Stem cell therapy holds considerable potential for treating dry eye syndrome, though it has yet to receive clinical approval. Aim This paper systematically quantifies the efficacy and safety of stem cell-based therapies in dry eye syndrome caused by Sjögren's syndrome, aiming to provide information for dry eye treatment efforts. Methods This systematic review collected literature published prior to 16 January 2026 in PubMed, Embase, and the Cochrane Library concerning stem cell therapy for Sjögren's syndrome-induced dry eye disease. Efficacy outcomes comprised: OSDI scores, along with changes in NIKBUT first, Oxford score, and Schirmer test results. Safety outcomes comprised commonly reported adverse events. Continuous outcomes were expressed as mean difference (MD), while dichotomous outcomes used single-group rates, both presented with 95% CI. All data analyses were conducted using Review Manager 5.4 software, adhering to the PRISMA guidelines. Results This meta-analysis included five studies involving 114 patients with dry eye syndrome. Results demonstrated that stem cell therapy significantly altered the OSDI score compared to pre-treatment levels: -15.10 (95% CI: -18.65, -11.56; P Conclusion This meta-analysis indicates that stem cell therapy effectively reduces OSDI scores, increase Schirmer test scores, and enhances tear film stability in dry eye syndrome caus
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.